サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1730904

免疫性血小板減少症の世界市場レポート 2025年

Immune Thrombocytopenia Global Market Report 2025

出版日
ページ情報
英文 175 Pages
納期
2～10営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=143.37円
免疫性血小板減少症の世界市場レポート 2025年
出版日: 2025年05月16日
発行: The Business Research Company
ページ情報: 英文 175 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

免疫性血小板減少症市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR5.9％で45億8,000万米ドルに成長します。予測期間中の成長は、血小板減少症の有病率の増加、ヘルスケア支出の増加、利用可能な治療法の拡大、血液疾患の有病率の増加、人口の高齢化などの要因によるものと考えられます。予測期間における主要動向としては、診断技術の進歩、デジタルヘルスソリューションの統合、併用療法へのシフト、遠隔医療の採用、診断における人工知能の導入などが挙げられます。

自己免疫疾患の有病率の増加は、今後の免疫性血小板減少症市場の成長を促進すると予想されます。自己免疫疾患は、免疫系が誤って体内の健康な細胞や組織を攻撃し、外敵として扱うことで発生します。この異常な免疫反応により炎症が起こり、様々な臓器や器官に損傷が生じます。自己免疫疾患の増加は、遺伝的素因、環境の影響、ライフスタイルの変化、診断の改善につながる認知度の向上などの要因によるものと考えられます。自己免疫疾患は、免疫系が血小板を攻撃・破壊したり、骨髄での血小板産生を阻害したりすることによって免疫性血小板減少症を引き起こします。例えば、2024年11月、ドイツを拠点とする団体Versorgungsatlas.deは、2022年、7,324万1,305人の被保険者のうち、630万4,340人が少なくとも1つの自己免疫疾患と診断され、有病率は8.61％と報告しました。したがって、自己免疫疾患の有病率の増加が免疫性血小板減少症市場の成長に寄与しています。

免疫性血小板減少症市場に参入している企業は、治療結果の改善、反応時間の短縮、患者のアドヒアランスの向上、血小板減少症管理におけるアンメットニーズへの対応などを目的として、特に静脈内（IV）療法における治療オプションの進展に注力しています。静脈内療法は、静脈ラインを通して患者の静脈に直接輸液、投薬、栄養補給を行うものです。例えば、2024年3月、オランダに本社を置くバイオテクノロジー企業であるアルジェンクスSEは、日本の厚生労働省が成人の原発性免疫性血小板減少症（ITP）の静脈内投与にVYVGARTを承認したと発表しました。この承認は、迅速な効果と持続的な血小板反応性を有する標的アプローチを提供し、自己免疫疾患治療における重要なギャップを解決するものであり、治療における重要な進歩を意味します。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場-マクロ経済シナリオ金利、インフレ、地政学、新型コロナウイルス感染症の影響と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

  • 世界の免疫性血小板減少症PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
  • 最終用途産業の分析
  • 世界の免疫性血小板減少症市場：成長率分析
  • 世界の免疫性血小板減少症市場の実績：規模と成長、2019～2024年
  • 世界の免疫性血小板減少症市場の予測：規模と成長、2024～2029年、2034年
  • 世界の免疫性血小板減少症総アドレス可能市場（TAM）

第6章 市場セグメンテーション

  • 世界の免疫性血小板減少症市場：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
  • 一次性免疫血小板減少症
  • 二次性免疫血小板減少症
  • 後天性免疫血小板減少症
  • 世界の免疫性血小板減少症市場：治療タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
  • コルチコステロイド
  • 静脈内免疫グロブリン
  • トロンボポエチン受容体作動薬
  • 免疫抑制療法
  • 世界の免疫性血小板減少症市場：流通チャネル別、実績と予測、2019～2024年、2024～2029年、2034年
  • 病院薬局
  • 小売薬局
  • オンライン薬局
  • 世界の免疫性血小板減少症市場、一次性免疫血小板減少症のサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
  • 急性原発性ITP
  • 慢性原発性ITP
  • 持続性一次性ITP
  • 世界の免疫性血小板減少症市場、二次性免疫血小板減少症のサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
  • 薬剤誘発性ITP
  • 感染関連ITP
  • 自己免疫疾患関連ITP
  • 世界の免疫性血小板減少症市場、後天性免疫血小板減少症のサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
  • 免疫介在性後天性ITP
  • 非免疫性ITP

第7章 地域別・国別分析

  • 世界の免疫性血小板減少症市場：地域別、実績と予測、2019～2024年、2024～2029年、2034年
  • 世界の免疫性血小板減少症市場：国別、実績と予測、2019～2024年、2024～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

  • 免疫性血小板減少症市場：競合情勢
  • 免疫性血小板減少症市場：企業プロファイル
    • Pfizer Inc.
    • Merck & Co. Inc.
    • Sanofi S.A.
    • Novartis AG
    • Amgen Inc.

第31章 その他の大手企業と革新的企業

  • Takeda Pharmaceutical Company Limited
  • Eli Lilly and Company
  • Intas Pharmaceuticals Ltd.
  • CSL Behring
  • Griffols
  • UCB Pharma
  • Kyowa Kirin
  • Sobi（Swedish Orphan Biovitrum）
  • 3SBio Inc.
  • BIoTest AG
  • Shionogi & Co. Ltd.
  • Ligand Pharmaceuticals
  • Rigel Pharmaceuticals
  • Symphogen
  • Hansa Biopharma

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、戦略

  • 免疫性血小板減少症市場、2029年：新たな機会を提供する国
  • 免疫性血小板減少症市場、2029年：新たな機会を提供するセグメント
  • 免疫性血小板減少症市場、2029年：成長戦略
    • 市場動向による戦略
    • 競合の戦略

第36章 付録

目次
Product Code: r34576

Immune thrombocytopenia is a rare autoimmune bleeding disorder in which the immune system mistakenly attacks and destroys platelets, which are crucial for blood clotting. This results in a low platelet count, impairing the blood's ability to form clots. Common symptoms include easy bruising, bleeding, and a rash consisting of small red spots.

The primary types of immune thrombocytopenia are primary immune thrombocytopenia (ITP), secondary immune thrombocytopenia, and acquired immune thrombocytopenia. Primary ITP occurs when the immune system incorrectly targets and eliminates platelets in the blood. Treatment options for ITP include intravenous immunoglobulin, thrombopoietin receptor agonists, and immunosuppressive therapy, which are distributed through hospital pharmacies, retail pharmacies, and online pharmacies.

The immune thrombocytopenia market research report is one of a series of new reports from The Business Research Company that provides immune thrombocytopenia market statistics, including the immune thrombocytopenia industry's global market size, regional shares, competitors with a immune thrombocytopenia market share, detailed immune thrombocytopenia market segments, market trends and opportunities, and any further data you may need to thrive in the immune thrombocytopenia industry. This immune thrombocytopenia market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The immune thrombocytopenia market size has grown strongly in recent years. It will grow from $3.43 billion in 2024 to $3.64 billion in 2025 at a compound annual growth rate (CAGR) of 6.2%. The growth during the historic period can be attributed to factors such as the rising prevalence of autoimmune disorders, an increase in the incidence of chronic liver diseases, greater access to healthcare services, expansion of healthcare infrastructure, and growing government support.

The immune thrombocytopenia market size is expected to see strong growth in the next few years. It will grow to $4.58 billion in 2029 at a compound annual growth rate (CAGR) of 5.9%. The growth during the forecast period can be attributed to factors such as the increasing prevalence of thrombocytopenia, rising healthcare spending, the expansion of available therapies, a growing prevalence of blood disorders, and an aging population. Key trends in the forecast period include advancements in diagnostic technologies, the integration of digital health solutions, a shift toward combination therapies, the adoption of telemedicine, and the incorporation of artificial intelligence in diagnostics.

The increasing prevalence of autoimmune diseases is expected to drive the growth of the immune thrombocytopenia market in the future. Autoimmune diseases occur when the immune system mistakenly attacks the body's healthy cells and tissues, treating them as foreign invaders. This abnormal immune response causes inflammation and damage to various organs and systems. The rise in autoimmune diseases can be attributed to factors such as genetic predispositions, environmental influences, lifestyle changes, and greater awareness leading to improved diagnosis. Autoimmune diseases can cause immune thrombocytopenia by prompting the immune system to attack and destroy platelets or interfere with their production in the bone marrow. For example, in November 2024, Versorgungsatlas.de, a Germany-based organization, reported that in 2022, among 73,241,305 insured individuals, 6,304,340 were diagnosed with at least one autoimmune disease, resulting in a prevalence rate of 8.61%. Therefore, the increasing prevalence of autoimmune diseases is contributing to the growth of the immune thrombocytopenia market.

Companies in the immune thrombocytopenia market are focusing on advancing therapeutic options, especially in intravenous (IV) therapies, to improve treatment outcomes, reduce response times, increase patient adherence, and address unmet needs in thrombocytopenia management. IV therapy involves delivering fluids, medications, or nutrients directly into a patient's vein through an intravenous line. For instance, in March 2024, Argenx SE, a biotechnology company based in the Netherlands, announced that the Japan Ministry of Health, Labor, and Welfare (MHLW) had approved VYVGART for intravenous administration in adults with primary immune thrombocytopenia (ITP). This approval marks a significant advancement in treatment, offering a targeted approach with rapid effects and sustained platelet response, addressing key gaps in autoimmune disease treatment.

In December 2024, Keros Therapeutics Inc., a U.S.-based biopharmaceutical company, formed a partnership with Takeda Pharmaceutical Industries Ltd. to develop and commercialize elritercept, a therapy designed to target disorders related to dysfunctional TGF-B signaling, including thrombocytopenia and other rare diseases. Takeda Pharmaceutical Industries Ltd., a Japan-based biopharmaceutical company, specializes in innovative treatments for thrombocytopenia and other rare diseases.

Major players in the immune thrombocytopenia market are Pfizer Inc., Merck & Co. Inc., Sanofi S.A., Novartis AG, Amgen Inc., Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Intas Pharmaceuticals Ltd., CSL Behring, Griffols, UCB Pharma, Kyowa Kirin, Sobi (Swedish Orphan Biovitrum), 3SBio Inc., Biotest AG, Shionogi & Co. Ltd., Ligand Pharmaceuticals, Rigel Pharmaceuticals, Symphogen, Hansa Biopharma, and Argenx.

North America was the largest region in the immune thrombocytopenia market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the immune thrombocytopenia market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The immune thrombocytopenia market consists of revenues earned by entities by providing services such as blood or platelet transfusions, splenectomy, plasma exchange, monitoring, and support services. The market value includes the value of related goods sold by the service provider or included within the service offering. The immune thrombocytopenia market also includes sales of pharmaceutical drugs, diagnostic kits and reagents, medical devices, platelet transfusion products, and supportive care products. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Immune Thrombocytopenia Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on immune thrombocytopenia market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for immune thrombocytopenia ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The immune thrombocytopenia market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Type: Primary Immune Thrombocytopenia; Secondary Immune Thrombocytopenia; Acquired Immune Thrombocytopenia
  • 2) By Treatment Type: Intravenous Immunoglobulin; Thrombopoietin Receptor Agonists; Immunosuppressive Therapy
  • 3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
  • Subsegments:
  • 1) By Primary Immune Thrombocytopenia: Acute Primary ITP; Chronic Primary ITP; Persistent Primary ITP
  • 2) By Secondary Immune Thrombocytopenia: Drug-Induced ITP; Infection-Associated ITP; Autoimmune Disorder-Related ITP
  • 3) By Acquired Immune Thrombocytopenia: Immune-Mediated Acquired ITP; Non-Immune Acquired ITP
  • Companies Mentioned: Pfizer Inc.; Merck & Co. Inc.; Sanofi S.A.; Novartis AG; Amgen Inc.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Immune Thrombocytopenia Market Characteristics

3. Immune Thrombocytopenia Market Trends And Strategies

4. Immune Thrombocytopenia Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Immune Thrombocytopenia Growth Analysis And Strategic Analysis Framework

  • 5.1. Global Immune Thrombocytopenia PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 5.2. Analysis Of End Use Industries
  • 5.3. Global Immune Thrombocytopenia Market Growth Rate Analysis
  • 5.4. Global Immune Thrombocytopenia Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
  • 5.5. Global Immune Thrombocytopenia Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
  • 5.6. Global Immune Thrombocytopenia Total Addressable Market (TAM)

6. Immune Thrombocytopenia Market Segmentation

  • 6.1. Global Immune Thrombocytopenia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Primary Immune Thrombocytopenia
  • Secondary Immune Thrombocytopenia
  • Acquired Immune Thrombocytopenia
  • 6.2. Global Immune Thrombocytopenia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Corticosteroids
  • Intravenous Immunoglobulin
  • Thrombopoietin Receptor Agonists
  • Immunosuppressive Therapy
  • 6.3. Global Immune Thrombocytopenia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • 6.4. Global Immune Thrombocytopenia Market, Sub-Segmentation Of Primary Immune Thrombocytopenia, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Acute Primary ITP
  • Chronic Primary ITP
  • Persistent Primary ITP
  • 6.5. Global Immune Thrombocytopenia Market, Sub-Segmentation Of Secondary Immune Thrombocytopenia, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Drug-Induced ITP
  • Infection-Associated ITP
  • Autoimmune Disorder-Related ITP
  • 6.6. Global Immune Thrombocytopenia Market, Sub-Segmentation Of Acquired Immune Thrombocytopenia, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Immune-Mediated Acquired ITP
  • Non-Immune Acquired ITP

7. Immune Thrombocytopenia Market Regional And Country Analysis

  • 7.1. Global Immune Thrombocytopenia Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 7.2. Global Immune Thrombocytopenia Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Immune Thrombocytopenia Market

  • 8.1. Asia-Pacific Immune Thrombocytopenia Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Immune Thrombocytopenia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.3. Asia-Pacific Immune Thrombocytopenia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.4. Asia-Pacific Immune Thrombocytopenia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Immune Thrombocytopenia Market

  • 9.1. China Immune Thrombocytopenia Market Overview
  • 9.2. China Immune Thrombocytopenia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.3. China Immune Thrombocytopenia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.4. China Immune Thrombocytopenia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Immune Thrombocytopenia Market

  • 10.1. India Immune Thrombocytopenia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.2. India Immune Thrombocytopenia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.3. India Immune Thrombocytopenia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Immune Thrombocytopenia Market

  • 11.1. Japan Immune Thrombocytopenia Market Overview
  • 11.2. Japan Immune Thrombocytopenia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.3. Japan Immune Thrombocytopenia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.4. Japan Immune Thrombocytopenia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Immune Thrombocytopenia Market

  • 12.1. Australia Immune Thrombocytopenia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.2. Australia Immune Thrombocytopenia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.3. Australia Immune Thrombocytopenia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Immune Thrombocytopenia Market

  • 13.1. Indonesia Immune Thrombocytopenia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.2. Indonesia Immune Thrombocytopenia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.3. Indonesia Immune Thrombocytopenia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Immune Thrombocytopenia Market

  • 14.1. South Korea Immune Thrombocytopenia Market Overview
  • 14.2. South Korea Immune Thrombocytopenia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.3. South Korea Immune Thrombocytopenia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.4. South Korea Immune Thrombocytopenia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Immune Thrombocytopenia Market

  • 15.1. Western Europe Immune Thrombocytopenia Market Overview
  • 15.2. Western Europe Immune Thrombocytopenia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.3. Western Europe Immune Thrombocytopenia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.4. Western Europe Immune Thrombocytopenia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Immune Thrombocytopenia Market

  • 16.1. UK Immune Thrombocytopenia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.2. UK Immune Thrombocytopenia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.3. UK Immune Thrombocytopenia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Immune Thrombocytopenia Market

  • 17.1. Germany Immune Thrombocytopenia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.2. Germany Immune Thrombocytopenia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.3. Germany Immune Thrombocytopenia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Immune Thrombocytopenia Market

  • 18.1. France Immune Thrombocytopenia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.2. France Immune Thrombocytopenia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.3. France Immune Thrombocytopenia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Immune Thrombocytopenia Market

  • 19.1. Italy Immune Thrombocytopenia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.2. Italy Immune Thrombocytopenia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.3. Italy Immune Thrombocytopenia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Immune Thrombocytopenia Market

  • 20.1. Spain Immune Thrombocytopenia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.2. Spain Immune Thrombocytopenia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.3. Spain Immune Thrombocytopenia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Immune Thrombocytopenia Market

  • 21.1. Eastern Europe Immune Thrombocytopenia Market Overview
  • 21.2. Eastern Europe Immune Thrombocytopenia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.3. Eastern Europe Immune Thrombocytopenia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.4. Eastern Europe Immune Thrombocytopenia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Immune Thrombocytopenia Market

  • 22.1. Russia Immune Thrombocytopenia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.2. Russia Immune Thrombocytopenia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.3. Russia Immune Thrombocytopenia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Immune Thrombocytopenia Market

  • 23.1. North America Immune Thrombocytopenia Market Overview
  • 23.2. North America Immune Thrombocytopenia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.3. North America Immune Thrombocytopenia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.4. North America Immune Thrombocytopenia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Immune Thrombocytopenia Market

  • 24.1. USA Immune Thrombocytopenia Market Overview
  • 24.2. USA Immune Thrombocytopenia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.3. USA Immune Thrombocytopenia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.4. USA Immune Thrombocytopenia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Immune Thrombocytopenia Market

  • 25.1. Canada Immune Thrombocytopenia Market Overview
  • 25.2. Canada Immune Thrombocytopenia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.3. Canada Immune Thrombocytopenia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.4. Canada Immune Thrombocytopenia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Immune Thrombocytopenia Market

  • 26.1. South America Immune Thrombocytopenia Market Overview
  • 26.2. South America Immune Thrombocytopenia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.3. South America Immune Thrombocytopenia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.4. South America Immune Thrombocytopenia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Immune Thrombocytopenia Market

  • 27.1. Brazil Immune Thrombocytopenia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.2. Brazil Immune Thrombocytopenia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.3. Brazil Immune Thrombocytopenia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Immune Thrombocytopenia Market

  • 28.1. Middle East Immune Thrombocytopenia Market Overview
  • 28.2. Middle East Immune Thrombocytopenia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.3. Middle East Immune Thrombocytopenia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.4. Middle East Immune Thrombocytopenia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Immune Thrombocytopenia Market

  • 29.1. Africa Immune Thrombocytopenia Market Overview
  • 29.2. Africa Immune Thrombocytopenia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.3. Africa Immune Thrombocytopenia Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.4. Africa Immune Thrombocytopenia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Immune Thrombocytopenia Market Competitive Landscape And Company Profiles

  • 30.1. Immune Thrombocytopenia Market Competitive Landscape
  • 30.2. Immune Thrombocytopenia Market Company Profiles
    • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.2. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.3. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.4. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.5. Amgen Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Immune Thrombocytopenia Market Other Major And Innovative Companies

  • 31.1. Takeda Pharmaceutical Company Limited
  • 31.2. Eli Lilly and Company
  • 31.3. Intas Pharmaceuticals Ltd.
  • 31.4. CSL Behring
  • 31.5. Griffols
  • 31.6. UCB Pharma
  • 31.7. Kyowa Kirin
  • 31.8. Sobi (Swedish Orphan Biovitrum)
  • 31.9. 3SBio Inc.
  • 31.10. Biotest AG
  • 31.11. Shionogi & Co. Ltd.
  • 31.12. Ligand Pharmaceuticals
  • 31.13. Rigel Pharmaceuticals
  • 31.14. Symphogen
  • 31.15. Hansa Biopharma

32. Global Immune Thrombocytopenia Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Immune Thrombocytopenia Market

34. Recent Developments In The Immune Thrombocytopenia Market

35. Immune Thrombocytopenia Market High Potential Countries, Segments and Strategies

  • 35.1 Immune Thrombocytopenia Market In 2029 - Countries Offering Most New Opportunities
  • 35.2 Immune Thrombocytopenia Market In 2029 - Segments Offering Most New Opportunities
  • 35.3 Immune Thrombocytopenia Market In 2029 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer